Pharmaceuticals, Biotechnology and Life Sciences
Actinium Pharmaceuticals on Monday announced key interim findings from the pivotal Phase 3 SIERRA trial of Iomab-B at 50% of total of 150-patient, compared to physician’s choice of salvage chemotherapy in patients age 55 and above with active, relapsed or refractory AML (Acute Myeloid Leukemia).
Biohaven Pharmaceutical has enrolled over 880 patients in less than nine months, in its pivotal Phase 3 clinical trial of troriluzole in generalized anxiety disorder (GAD).
Bausch Health Companies’s gastroenterology business, Salix Pharmaceuticals, one of the largest specialty pharmaceutical companies in the world committed to the…
ANN ARBOR, Mich.–(BUSINESS WIRE)–$KBLB #KBLB–Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider silk based fibers, announced…
Institutional Shareholder Services has recommended that shareholders vote on the GREEN consent card in support of Velan’s director nominees, Dr.…
Iverics’ bio’s Zimura meet primary endpoint in Phase 2b Trial in certain Macular Degeneration, as overall data suggest a dose…
DETROIT–(BUSINESS WIRE)–Please replace the caption for release dated October 25, 2019 with the accompanying corrected caption.
Four life sciences leaders bring deep expertise to support CBSA members, as they join as new members of the Board…
FDA post approval study shows timely identification of right heart failure and early use Abiomed’s ImMpella RP leads to higher…
Spectrum Pharmaceuticals has submitted updated BLA to the USFDA, for Rolontis, based on two large pivotal randomized controlled studies that…